The prostate-specific antigen test determines the blood level of PSA, an enzyme formed by the prostate. Prostate-specific antigen is a serine protease comparable to kallikrein-3. Its function is to liquefy gelatinous semen once ejaculation is carried out, permitting spermatozoa to steer through the uterine cervix. Prostate-specific antigen testing is contentious and may bring unnecessary and damaging effects in some patients. Ever since PSA screening was initiated in Canada, more than a million men in the country have been diagnosed and cured of prostate cancer (Pickles 4). It has been projected that the vast majority, more than 90% of men, get no benefit from this diagnosis. Even though a person makes a positive assumption regarding the advantage of screening, less than 10% of men getting a positive diagnosis to receive any benefit at all from it. Positive assumption refers to the entire decline in prostate cancer deaths witnessed since the opening of PSA testing. Other studies, however, point to the achievement of the prostate-specific antigen test in dropping death because of prostate cancer (Craig 24). The Prostate Cancer Research Foundation of Canada (PCRFC) study, observed in the New Canadian Journal of Medicine in February 2009, that screening caused a 20% decrease in prostate cancer deaths.